MethylGene Inc. (TSX:MYG) today disclosed preclinical data including in vivo efficacy results regarding the identification of second generation HDAC inhibitors and multi-targeted kinase inhibitors. The information was disclosed in two poster sessions which were displayed at the 97th American Association for Cancer Research (AACR) Annual Meeting in Washington, DC from April 1-5, 2006.
